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Citrullination is the post-translational hydrolysis of peptidyl-arginines to form peptidyl-citrulline, 
a reaction that is catalyzed by the protein arginine deiminases (PADs), a family of calcium-
regulated enzymes.  Aberrantly increased protein citrullination is associated with a slew of 
autoimmune diseases (e.g., rheumatoid arthritis (RA), multiple sclerosis, lupus, and ulcerative 
colitis) and certain cancers.  Given the clear link between increased PAD activity and human 
disease, the PADs are therapeutically relevant targets.  Herein, we report the development of 
next generation cell permeable and “Clickable” probes (BB-Cl-Yne and BB-F-Yne) for covalent 
labeling of the PADs both in vitro and in cell-based systems.  Using advanced chemoproteomic 
technologies, we also report the off targets of both BB-Cl-Yne and BB-F-Yne.  The probes are 
highly specific for the PADs, with relatively few off targets, especially BB-F-Yne, suggesting 
the preferential use of the fluoroacetamidine warhead in next generation irreversible PAD 
inhibitors.  Notably, these compounds can be used in a variety of modalities, including the 
identification of off-targets of the parent compounds and as ABPPs in target engagement assays 









Aberrantly upregulated protein citrullination is associated with a slew of autoimmune 
diseases (e.g., rheumatoid arthritis (RA), multiple sclerosis, lupus, and ulcerative colitis), as well 
as certain cancers.1, 2  Given these disease links, the protein arginine deiminases (PADs), the 
enzymes that catalyze this reaction, have garnered significant recent interest.  The most deeply 
investigated disease associated with aberrantly increased PAD activity is RA, where these 
patients produce autoantibodies targeting numerous citrullinated proteins (e.g., citrullinated 
keratin, fibrin, vimentin and enolase).3-7  Importantly, the presence of these autoantibodies is the 
most specific diagnostic test available for RA.  Moreover, these autoantibodies are present in 
patients’ sera 4-5 years before clinical onset, and higher titers are associated with a more severe 
clinical outcome.7-9  Thus, the presence of these anti-citrullinated protein antibodies (i.e., ACPA) 
is highly predictive of both disease incidence and severity.  In addition to ACPAs, PAD2 and 
PAD4 are released by immune cells into the synovial joints of patients with RA where they 
remain active and citrullinate proteins.  Within the joint, these citrullinated proteins then bind 
ACPAs,7, 10, 11 thereby setting up a classic positive feedback loop that recruits additional immune 
cells into the joint, the release of additional PAD isozymes into the synovium and enhanced 
protein citrullination and consequent inflammation.7  
Although the specific cells that release PAD isozymes into the joints of RA patients is 
still debated, one likely source is neutrophils.  Neutrophils are the predominant white blood cell 
in humans and are generally the first responders to signs of infection/inflammation.  Depending 
on the environmental cues, a subset of these cells will undergo a novel form of cell death known 
as Neutrophil Extracellular Trap formation (NET) or NETosis.12-14  During this process, the 
chromatin decondenses and histones and other proteins are hypercitrullinated ultimately resulting 
in the ejection of chromatin fibers from the cell to form a web like structure that can trap 
pathogens (e.g. bacteria, fungi, viruses) as well as promote the formation of blood clots.12-14 
Notably, neutrophils have long been known to be important players in the development and 
progression of RA as they are a predominant cell type in the synovial fluid of RA patients.15, 16 
Enhanced NETosis, as is observed in RA,12 also results in the exposure of citrullinated 
autoantigens, which is key to the progression of RA, and is additionally thought to be the source 
of extracellular PADs.4, 12  How the PADs contribute to other inflammatory diseases is less well 
defined, but characteristic features include enhanced citrullination in the inflamed regions, 
suggesting that aberrant NETosis may contribute to these diseases as well.  In addition, since the 
PADs are histone modifying enzymes that contribute to the epigenetic control of gene 
expression, there is emerging evidence to suggest that enhanced PAD activity promotes an 
inflamed state by altering the expression and/or activity of key cytokines and chemokines.17, 18  
The role that the PADs play in these diseases is further highlighted by the efficacy of 
several PAD inhibitors in a variety of pre-clinical disease models.  Specifically, the first-
generation irreversible inhibitor Cl-amidine (1, Figure 1) has demonstrated efficacy in animal 
models of rheumatoid arthritis, lupus, ulcerative colitis, breast cancer, and atherosclerosis.12, 19-27 
The therapeutic importance of the PADs was further highlighted by the second generation 
inhibitor, BB-Cl-amidine (3), which has shown enhanced efficacy over Cl-amidine (1) in animal 
models of lupus and RA.17, 28, 29  Moreover, the allosteric inhibitor GSK199 also shows efficacy 
in an RA model.30  Together, these findings have validated the PADs as viable therapeutic 
targets for a wide range of inflammatory conditions. 
 
The PAD reaction involves the hydrolysis of the guanidinium group of arginine to 
generate citrullinated proteins.1, 31, 32  This reaction, variably termed citrullination or deimination, 
is a calcium-dependent process wherein calcium binding triggers a conformational change that 
moves a nucleophilic cysteine residue into the active site, resulting in a >10,000-fold increase in 
PAD activity.33, 34  There are five PAD isozymes (PADs 1-4 and 6)1, 31, 32 with unique cellular 
and tissue distribution patterns, however, only PADs 1-4 are catalytically active.  It is also 
important to note that the PADs are uniquely distributed both within the cell and throughout the 
body. Specifically, all the PADs can be found in the cytoplasm while only PADs 1, 2, and 4 are 
also localized in the nucleus.35-37  When it comes to distribution throughout the body, PAD2 is 
expressed in most tissues and cell types, PAD1 and PAD3 are principally expressed in the skin 
and hair follicles, PAD6 in oocytes, and PAD4 primarily in neutrophils and other myeloid 
derived cells.31  While PAD2 and PAD4 play a significant role in the development of RA,3, 38  
PAD2 is also overexpressed in luminal breast cancer cells and its expression correlates with the 
level of the HER2 protooncogene.27, 36, 39 
Cl-amidine (1) and the related PAD inhibitor F-amidine (2, Figure 1) irreversibly inhibit 
the PADs by covalently modifying an active site cysteine (Cys645 and 647 in PAD4 and PAD2, 
respectively).  Taking advantage of the conserved nature of this catalytic cysteine, we previously 
reported the development of activity-based protein profiling (ABPP) probes targeting the PADs. 
These probes include Rhodamine-conjugated F-amidine (RFA)40 which labels all 4 active PAD 
isozymes (PADs 1-4) and was used to identify novel inhibitors of both PAD2 and PAD4.41, 42 
“Clickable” versions of this probe were also developed and demonstrated their ability to label 
and isolate the PADs under a variety of conditions.43  
Despite these early advances, the peptidic nature of these first-generation inhibitors and 
ABPPs possessed a number of limitations including their susceptibility to proteolysis and poor 
membrane permeability.28  This prompted the development of second-generation inhibitors 
predicated on improving metabolic stability and membrane permeability by substituting the C-
terminal carboxamide with a benzimidazole moiety.28  This progression led to the discovery of 
BB-Cl-amidine (3) which has shown enhanced efficacy in a number of cell-based assays as well 
as animal models.17, 28, 29, 44  Specifically, BB-Cl-amidine (3) demonstrated an ability to block 
NETosis while improving efficacy in animal models of lupus and RA.17, 28, 29   In addition to 
further validating the PADs as important therapeutic targets, this scaffold also provided a novel 
platform for the development of next generation of ABPPs.  
Herein we report the development of BB-Cl-Yne (5) and BB-F-Yne (6) for labeling the 
PADs both in vitro and in cell-based systems (Figure 1).  These probes covalently modify the 
catalytic cysteine residue conserved in all PAD isozymes and present a handle for a subsequent 
copper catalyzed azide-alkyne cycloaddition reaction (CuAAC)45 with either TAMRA-N3 or 
Biotin-N3.  The probes described herein are highly specific with relatively few off targets.  Using 
advanced chemoproteomics technology we also report for the first time the off targets of both 
BB-Cl-Yne and BB-F-Yne. Notably, these compounds can be used in a variety of modalities, 
including the identification of off-targets of the parent compounds and as ABPPs in target 
engagement assays to demonstrate the efficacy of PAD inhibitors.  Moreover, we expect that 
these probes will aid in furthering our understanding of PAD biology by detecting PADs in 
complex biological systems as well as ultimately identifying novel proteins and signaling 
pathways that interact with and/or regulate PAD activity.   
  
RESULTS AND DISCUSSION 
Probe Design.  Three key features that we considered during the design of our next generation 
PAD-targeted ABPPs were: 1) cell permeability; 2) metabolic stability; and 3) alkyne position 
for optimal CuAAC.  The first two features were implemented by utilizing the next generation 
PAD inhibitors, BB-Cl-amidine (3) and BB-F-amidine (4) as the core scaffold; this scaffold 
shows improved cell permeability and metabolic stability as compared to the first-generation 
counterparts, Cl-amidine (1) and F-amidine (2) (Figure 1A).  Considering the structure of BB-Cl-
amidine (3) and BB-F-amidine (4), we hypothesized that incorporation of an alkyne on either the 
benzimidazole moiety or the biphenyl group would optimally facilitate the copper catalyzed 
azide-alkyne cycloaddition reaction (CuAAC) between the probe and either TAMRA-N3 or 
Biotin-N3. 
Key to developing these “Clickable” probes was the determination of the co-crystal 
structure of BB-F-amidine (4) bound to PAD4 (Figure 1B).46  Close examination of this co-
crystal structure (Figure 1B) shows that the benzimidazole moiety binds deep within the active 
site.  By contrast, the biphenyl group orients towards the solvent.  Figure 1C illustrates the 
potential binding of this benzimidazole-based scaffold to active PAD2 through an overlay of the 
PAD4-BB-F-amidine (4) co-crystal structure with holoPAD2 (PDB: 4N2C).47  This overlay 
indicates that BB-F-amidine (4) binds to PAD2 in a similar fashion to PAD4 where the biphenyl 
group is solvent exposed and the benzimidazole moiety is buried within the substrate binding 
pocket.  These data suggested that placement of the alkyne at the 4-position of the biphenyl 
moiety would allow for optimal CuAAC after covalent modification of the catalytic cysteine 
conserved in all active PAD isozymes; PAD6 is not catalytically active.48  
Probe Synthesis.  The synthesis of these clickable probes (Scheme 1) commenced with the 
generation of key intermediate 16 through a previously published method.28, 49  Briefly, Fmoc-
Orn(Boc)-OH underwent HBTU-mediated amide coupling with phenylenediamine, followed by 
acid-catalyzed cyclization to form the benzimidazole moiety.  Subsequent treatment with 
piperidine resulted in decarboxylation of the Fmoc protecting group giving 16.  This intermediate 
was then subjected to HBTU-mediated amide coupling with biphenyl carboxylic acid 13 to give 
Boc-protected intermediate 17.  Subsequent acid catalyzed decarboxylation of the side chain Boc 
group followed by installation of either the chloroacetamidine or fluoroacetamidine or warhead 
gave desired probes 5 (BB-Cl-Yne) and 6 (BB-F-Yne) in good yield.  
Probe Validation – Potency and in vitro labeling.  To initially establish the utility of these 
“clickable” probes, we first determined kinact/KI values to assess their ability to inhibit PADs 1, 2, 
3, and 4 (Table1, Figures S1-S2, and Table S1).  Importantly, the kinact/KI values for BB-Cl-Yne 
(5) and BB-F-Yne (6) are within 3-fold of the parent compounds BB-Cl-amidine and BB-F-
amidine indicating that the additional alkyne moiety does not significantly impact potency, 
consistent with our modeling (Figure 1B-C).  Next, we evaluated the ability of BB-F-Yne and 
BB-Cl-Yne to covalently modify recombinant PADs and undergo a subsequent click reaction 
with TAMRA-N3.  Figures 1D-E and Figures S3-S4 illustrate the ability of these probes to 
effectively label PADs 1-4 in a dose-dependent manner down to probe concentrations as low as 
250 nM.  Notably, the sensitivity of the probes is as low as 375 fmol with BB-F-Yne (Figure 1F) 
and 756 fmol with BB-Cl-Yne (Figure 1G).  Despite the two probes exhibiting similar potencies 
against PAD2, the slightly lower limit of detection may be attributable to the higher selectivity of 
BB-F-Yne compared to BB-Cl-Yne (see below).  
Probe validation – Labeling in cells.  Having demonstrated their ability to label recombinant 
PADs, we next evaluated their ability to label the PADs in cell-based systems.  Specifically, 
PAD2-overexpressing HEK293T cell lines were treated with BB-F-Yne and BB-Cl-Yne in the 
presence of a calcium ionophore (i.e., ionomycin) (Figure 2A).  Cells were then harvested, lysed 
by sonication, and then “Clicked” with TAMRA-N3.  Notably, BB-F-Yne labeled a single 
prominent band at the correct molecular weight for PAD2 (Figure 2B), even when used at 
concentrations as high as 25 µM.  This level of selectivity is remarkable.  In agreement with our 
in vitro results, BB-Cl-Yne did not label PAD2 as efficiently as BB-F-Yne (Figure 2 C), again 
indicating the superior selectivity of BB-F-Yne.  The diminished labeling ability of BB-Cl-Yne 
may be due to the increased reactivity of the chloro-warhead, compared to the fluoro-warhead,41, 
43 which increases the number of off targets such that a smaller amount of the probe is available 
to label PAD2.  
 To demonstrate their utility in assessing target engagement, BB-F-Yne and BB-Cl-Yne 
were subjected to competition experiments.  Briefly, PAD2-ovexpressing HEK293T cell lysates 
were incubated with increasing concentrations of either BB-F-amidine or BB-Cl-amidine in the 
presence of CaCl2 and were then treated with a fixed concentration BB-F-Yne or BB-Cl-Yne. 
Labeled lysates were “Clicked” with TAMRA azide and probe modified proteins were visualized 
by fluorescence.  Both BB-F-amidine and BB-Cl-amidine dose dependently decrease the labeling 
of PAD2 (Figure S6 and S7) by BB-F-Yne and BB-Cl-Yne, thereby demonstrating their ability 
to assess target engagement.   
To further illustrate the versatility of these probes, PAD2-ovexpressing HEK293T cell 
lysates were treated with either BB-F-Yne or BB-Cl-Yne and then “Clicked” with Biotin-N3 
(Figure 2D).  These lysates were then incubated with streptavidin-agarose beads, washed and 
probed for PAD2 or biotinylated proteins as shown in Figure 2D.  Both BB-F-Yne and BB-Cl-
Yne show a similar ability to label and isolate PAD2 (Figure 2E and F).  The small amount of 
PAD2 isolated in the untreated control may be due to the ability of streptavidin-agarose beads to 
isolate autocitrullinated PAD2; the urea moiety of citrulline is structurally related to biotin and 
we consistently observe streptavidin binding to autocitrullinated PADs (data not shown).  Note 
that PAD2 is expressed at ~0.8% of total proteins in our PAD2 overexpressing cell line (Figure 
S8).   
Chemoproteomics experiments.  Next, we employed a chemoproteomic approach to identify 
the targets of these two probes.  Specifically, HEK293T PAD2 overexpressing cell lysates were 
treated with BB-F-Yne (25 µM), BB-Cl-Yne (2.5 µM), or DMSO for one hour (Figure 3A).  
These concentrations were chosen because they correspond to the EC50 values of the parent 
compounds in cellular citrullination experiments.46  Labeled proteomes were then “Clicked” with 
Biotin-N3 in the presence of TBTA and CuSO4.  The clicked lysates were then isolated on 
streptavidin agarose beads followed by on-bead trypsin digestion and subsequent LC/LC-
MS/MS.  Protein identities were determined by database searches using the SEQUEST 
algorithm.  Relative quantitation of probe labeled proteins in probe and DMSO treated samples 
was achieved by spectral counting.   
Consistent with our Tamra-N3 labeling data, BB-F-Yne selectively enriched PAD2 with 
few off targets (Figure 3B and 3D).  Figure 3B depicts the difference in spectral counts (ΔSC) 
between DMSO and BB-F-yne-treated samples for proteins identified in two biological 
replicates.  Proteins along the diagonal are consistently enriched in the BB-F-yne sample and 
those above one standard deviation (1 SD) are considered statistically significant.  Figure 3D 
depicts the average spectral count data plotted against the probe/DMSO spectral count ratio, 
which provides a relative measure of probe selectivity.  Those proteins with high spectral counts 
and high probe/DMSO ratios are significantly enriched.  Both plots demonstrate the remarkable 
selectivity of BB-F-Yne.   
By contrast, BB-Cl-Yne reacted with PAD2 and a modest number of off targets in this in 
vitro experiment.  These proteins include Heterogeneous Nuclear Ribonucleoprotein U 
(HNRPU), Clathrin heavy chain 1 (CLTC), Bifunctional glutamate/proline-tRNA ligase (EPRS), 
Tubulin beta chain (TUBB) and Actin beta chain (ACTB).  Most of these proteins are highly 
abundant, contain reactive cysteines that covalently react with cysteine-targeted electrophiles, 
and have been found in other proteomic screens.50  Nevertheless, it is important recognize that 
PAD2 is amongst the most prominent proteins labeled by BB-Cl-Yne (Figure 3C and 3E), 
thereby indicating the preferential targeting of this protein by both this probe and likely the 
parent compound BB-Cl-amidine.  The lower fold enrichment relates to background binding of 
PAD2 to the streptavidin beads, which, as noted above, relates to the ability of autocitrullinated 
PADs to bind weakly to streptavidin-agarose.  
Because the proteomic experiments were performed with cell lysates, we next wished to 
confirm that the identified proteins were labeled in cells (Figure 4A).  We focused on HNRPU, 
CLTC), EPRS), β-tubulin, and β-Actin because they were prominent off targets in our 
chemoproteomic screen.  GAPDH and RPL were included as negative controls because they 
were slightly elevated but the data were not statistically significant.  For these experiments, HEK 
cells overexpressing PAD2 were treated with BB-Cl-Yne (2.5 μM) and BB-F-Yne (25 μM) and 
then clicked to biotin azide.  These concentrations were chosen because they correspond to the 
EC50 values for BB-F-amidine and BB-Cl-amidine in cellular citrullination experiments.
46  
Proteins were then isolated using streptavidin beads and the bound proteins were detected by 
western blotting after SDS-PAGE.  In parallel we performed similar experiments in cell lysates.  
Consistent with our proteomic and labeling studies (see above), BB-F-Yne selectively isolated 
PAD2.  Remarkably, BB-Cl-Yne was also selective and failed to isolate β-tubulin, β-Actin, 
clathrin, HSP90, GAPDH, and EPRS.  By contrast, we did confirm that BB-Cl-Yne modifies β-
tubulin, β-Actin, clathirin, HSP90 and EPRS but not GAPDH and RPL3 when cell lysates are 
treated with BB-Cl-Yne at 2.5 μM (Figure 4B).  When cells were treated with a higher 
concentration of BB-Cl-Yne (10 μM), we did detect some labeling of β-tubulin and HSP90, but 
still failed to label β-Actin and GAPDH (Figure 4C).  Overall, these data indicate that the 
selectivity of BB-Cl-Yne in cells is higher than that in cell lysates.  The enhanced selectivity is 
likely due to a combination of factors including cell permeability which for low permeable 
compounds would adversely impact the cellular concentration of the probe and thereby improve 
cellular selectivity.  Additionally, it is important to recognize that proteins like actin and tubulin 
adopt complex structures in cells, as compared to lysates, and as such their reactive cysteines 
may not be susceptible to modification.   
 
Conclusions.   
In summary, we describe the development of two new PAD targeted ABPPs, BB-F-Yne 
(6) and BB-Cl-Yne (5), that show enhanced cellular uptake and efficient labeling of the PADs in 
cells.  We predict that these compounds will be used in a variety of modalities, including as 
ABPPs in target engagement assays to demonstrate the efficacy of PAD inhibitors.  Moreover, 
we expect that these probes will aid in furthering our understanding of PAD biology by detecting 
PADs in complex biological systems as well as ultimately identifying novel proteins and 
signaling pathways that interact with and/or regulate PAD activity.  Our chemoproteomic data 
also highlights several features of the haloacetamidine warheads present in BB-F-amidine, BB-
Cl-amidine, and related compounds.  First, the fluoroacetamidine warhead is fairly non-reactive 
and in the context of the BB-F-amidine scaffold facilitate the isolation of only a single protein, 
i.e. PAD2, despite being tested at 25 µM.  Such selectivity is remarkable and unprecedented for 
thiol reactive warheads.  Second, BB-Cl-amidine reacts with a wider array of proteins and this 
feature likely explains the generally higher toxicity of chloroacetamidine containing 
compounds.46  Nevertheless, BB-Cl-Yne still shows high selectivity when applied to intact cells.  
This feature, along with its greater cell permeability, likely explains why BB-Cl-amidine has 
shown remarkable efficacy in animal models of RA and lupus.17, 28, 29  Projecting forward, we 
suggest that a primary focus should be placed on developing fluoroacetamidine-based 
irreversible inhibitors of the PADs due to the inherent specificity conferred by this warhead.  
  
METHODS 
Materials.  PADs 1, 2, 3 and 4 were purified as reported.22, 51  HEK293T and HEK293T cells 
stably expressing human PAD2 (HEK293T/PAD2) were cultured as previously described.41 
Bioin-TEV-N3 was synthesized as previously reported.
52  TAMRA-N3 was obtained from 
Lumiprobe.   
 
Inactivation Kinetics.  Inactivation kinetic parameters were determined by incubating PAD1, 2, 
or 4 (2.0 µM) or PAD3 (5.0 µM) in a pre-warmed (10 min, 37 °C) inactivation mixture (50 mM 
HEPES pH 7.6, 10 mM CaCl2, and 2 mM DTT, with a final volume of 60 µL) containing various 
concentrations of inhibitor.  Aliquots for were removed at various time points and added to a pre-
warmed (10 min, 37 °C) reaction mixture (50 mM HEPES pH 7.6, 50 mM NaCl, 10 mM CaCl2, 
2 mM DTT, and 10 mM BAEE or 10 mM BAA in the case of PAD3).  The final dilution from 
the pre-incubation assay to the activity assay was 10-fold.  After 15 min, reactions were 
quenched in liquid nitrogen and citrulline production quantified using the COLDER assay.34, 53  
Data were plotted as a function of time and fit to eq 1, 
v = voe
-kt     eq 1, 
using GraFit version 5.0.11, where v is velocity, vo is initial velocity, k (equal to kobs) is the pseudo-
first order rate constant of inactivation, and t is time.  When saturation was reached upon plotting 
kobs versus inactivator concentration, the data were fit to eq 2, 
kobs=kinact[I]/(KI+[I])    eq 2, 
using GraFit version 5.0.11, where kinact corresponds to the maximal rate of inactivation and KI is 
the concentration of inhibitor that gives half-maximal inactivation.  If the plot of kobs versus [I] 
was linear and did not saturate, then the value for kinact/KI equaled the slope of the line. 
 
In vitro labeling of PADs dose dependently with BB-F-Yne (6) and BB-Cl-Yne (5).  Increasing 
concentrations of BB-F-Yne (6) or BB-Cl-Yne (5) (0 to 10 µM) were incubated with recombinant 
PADs (1 µM) in the presence of CaCl2 (2 mM) in 1x PBS at 37 ºC for 1 h.  The probe labeled 
enzymes were coupled to TAMRA-N3 (20 µM) in the presence of 1X TBTA (0.31 mM), sodium 
ascorbate (2 mM) and freshly prepared CuSO4 (1 mM).  The tubes were gently tumbled for 1 h.  
The reactions were quenched with 6x SDS loading buffer and separated by SDS-PAGE (12.5% 
gel).  The bands were visualized by scanning the gel in a typhoon scanner (approximate 
excitation/emission maxima ~546/579, respectively). 
 
In vitro labeling of PAD2 with BB-F-Yne (6) and BB-Cl-Yne (5) to determine their limit of 
detection (LOD).  BB-F-Yne (6) or BB-Cl-Yne (5) (10 µM) were incubated with decreasing 
concentrations of recombinant PAD2 (1.0 to 0.025 µM) in the presence of CaCl2 in 1x PBS (2 
mM) at 37 ºC for 1 h.  The probe labeled enzymes were coupled to TAMRA-N3 (20 µM) in the 
presence of 1X TBTA (0.31 mM), sodium ascorbate (2 mM) and freshly prepared CuSO4 (1 mM).  
The tubes were gently tumbled for 1 h.  The reactions were quenched with 6x SDS loading buffer 
and separated by SDS-PAGE (12.5% gel).  The bands were visualized by scanning the gel in a 
typhoon scanner (approximate excitation/emission maxima ~546/579, respectively). 
 
Cellular labeling of PAD2 with BB-F-Yne and BB-Cl-Yne in ionomycin stimulated 
HEK293T/PAD2 cells.  HEK293T cells stably expressing human PAD2 (HEK293T PAD2) were 
cultured as previously described.41  Cells were grown to ~80% confluence (8 x 106 cells), 
trypsinized, and trypsin activity quenched with complete media.  The cells were harvested by 
centrifugation at 1000 x g for 2 min and washed 4x with 1x PBS.  Cells were resuspended in PBS 
at 8 x 106 cells/mL and 4 x 105 cells were added to 0.65 mL tubes for subsequent assays. 
HEK293T PAD2 cells were treated with increasing concentrations of BB-F-Yne or BB-
Cl-Yne (0 to 50 µM) in the presence of CaCl2 (2 mM) at 37 ºC.  After 30 min, ionomycin (5 µM) 
was added and the cells incubated for 1 h followed by sonication at 4 ºC for 1 h.  Lysates were 
cleared by centrifugation at 21,000 x g for 15 min.  The soluble protein fraction was isolated and 
quantified by the Detergent Compatible assay (DC assay, Biorad).  Lysates (2 μg/μL, 50 μL total) 
were “Clicked” with TAMRA-N3 (20 µM), 1X TBTA (0.3 mM), sodium ascorbate (2 mM) and 
freshly prepared CuSO4 (1 mM).  The tubes were gently tumbled for 2 h.  The reactions were 
quenched by the addition of 6x SDS loading buffer and separated by SDS-PAGE (12.5% gel).  The 
bands were visualized by scanning the gel in a typhoon scanner (approximate excitation/emission 
maxima ~546/579, respectively).   
Lysates (2 μg/μL, 500 μL total) were also “Clicked” with Biotin azide (100 µM), 1X TBTA 
(0.3 mM), sodium ascorbate (2 mM) and freshly prepared CuSO4 (1 mM).  The tubes were gently 
tumbled for 2 h.  The cloudy solution was transferred to a microconcentrator (10 kDa molecular 
weight cutoff) and centrifuged at 10,000 x g for 5 min at 4 ºC to remove the excess biotin azide. 
The protein was then resolubilized in 1X PBS with 0.2% SDS.  Resolubilized protein samples 
were incubated with 100 μL streptavidin-agarose beads (Thermo Scientific) at 4 °C for 16 h.  The 
solutions were then incubated at room temperature for 1 h.  The beads were washed with 0.2% 
SDS/PBS, PBS, and water.  The beads were pelleted by centrifugation (1,600 x g, 3 min) between 
washes.  To the washed beads, 2X SDS loading buffer was added and heated in a 95 °C heat block 
for 15 min.  The resolubilized protein was separated by SDS-PAGE (4 – 20 % gel) and transferred 
to PVDF membranes (Biorad) at 150 V for 60 min.  The membranes were analyzed for PAD2 and 
for other proteins.  
Competition experiments. HEK293T PAD2 cell lysates (100 μg) were treated with increasing 
concentrations of BB-Cl-amidine or BB-F-amidine (0 – 200 μM) in the presence of CaCl2 (1 mM) 
at 37 ºC.  After 15 minutes, BB-Cl-Yne or BB-F-Yne (25 μM) was added and the lysates were 
incubated for 1 h.  Lysates (100 μg, 50 μL total) were “Clicked” with TAMRA-N3 (20 µM), 1X 
TBTA (0.3 mM), and freshly prepared CuSO4 (1 mM).  The tubes were gently tumbled for 2 h.  
The reactions were quenched by the addition of 6x SDS loading buffer and separated by SDS-
PAGE (4-20 % gel).  The bands were visualized by scanning the gel in a typhoon scanner 
(approximate excitation/emission maxima ~546/579, respectively).  Western blot analysis of the 
lysates was performed to detect the presence of PAD2. 
 
Chemoproteomic analysis of cellular PAD2 labeled with BB-F-yne and BB-Cl-yne.  Cell 
lysates (2 mg lysate per tube) prepared from HEK293T PAD2 expressing cells were labeled with 
BB-F-yne (25 µM) and BB-Cl-yne (1 μM) by incubating at 37 °C for 1h.   The probes were 
‘Clicked’ to biotin azide (100 µM) in the presence of 1X TBTA (0.3 mM) and CuSO4 (1 mM) 
for 2 h at room temperature. Samples were mixed well by vortexing them every 15 min.  The 
reaction mixture was then centrifuged and the pellet was washed with methanol and resuspended 
in 1.2% SDS in PBS (w/v) followed by sonication and heating (5 min, 80 °C).  The SDS-
solubilized samples were diluted with PBS (5 mL) for a final SDS concentration of 0.2%.  The 
solutions were incubated with 100 μL of streptavidin agarose beads (Thermo Fisher Scientific) at 
4 °C for 16 h.  The solutions were then incubated at room temperature for 3 h.  The beads were 
washed with 6M urea in PBS (2 × 5 mL), 0.2% SDS/PBS (2 × 5 mL), PBS (3 × 5 mL), and water 
(3 × 5 mL).  The beads were pelleted by centrifugation (1,400 x g, 3 min) between washes.  The 
washed beads were suspended in 6 M urea in PBS (500 μL) and 10 mM dithiothreitol (from 20x 
stock in water) and placed in a 65 °C heat block for 15 min.  Iodoacetamide (20 mM, from 20x 
stock in water) was then added to the samples and allowed to react at 37 °C for 30 min. 
Following reduction and alkylation, the beads were pelleted by centrifugation (1,400 x g, 3 min) 
and resuspended in a premixed solution of 2 M urea in PBS (200 μL), 100 mM CaCl2 in water (2 
μL), and trypsin (4 μL of 20 mg reconstituted in 40 μL of trypsin buffer).  The digestion was 
allowed to proceed overnight at 37 °C.  The digested peptides were separated from the beads by 
centrifugation and the beads were washed twice with 50 μL of H2O. Formic acid (15 μL) was 
added to the samples, and the samples were stored at −80 °C until MS analysis.  
 
LC/LC-MS/MS and Data Processing.  Mass Spectrometry was performed using a Thermo Fisher 
LTQ Orbitrap Discovery mass spectrometer in conjunction with Agilent 1200 series HPLC.  
Enriched and digested peptide samples were pressure-loaded onto 250 m fused silica desalting 
column packed with 4 cm of Aqua C18 reverse phase resin (Phenomenex).  Peptides were eluted 
onto a biphasic 100 m fused silica column with a 5 m tip.  The column was packed with 3 cm 
Partisphere strong cation exchange resin (SCX, Whatman) followed by 10 cm of C18 resin.  
Elution took place using a gradient from 5% Buffer A (95% water, 5% acetonitrile, 0.1% formic 
acid), to 100% Buffer B (20% water, 80% acetonitrile, 0.1% formic acid).  The peptides were 
detached from the SCX onto the C18 resin and into the mass spectrometer using distinct salt 
elutions (95% high-purity water, 5% Optima-grade acetonitrile, 0.1% formic acid and 500 mM 
ammonium acetate)52.  The flow rate through the column was 250 nL/min, with a spray voltage of 
2.75 kV.  With dynamic exclusion enabled, each full MS1 scan (400-1800 MW) was followed by 
8 high-resolution, data-dependent scans of the nth most intense ion.  
 The tandem MS data from the multidimensional LC/LC-MS/MS protocol (MudPIT) was 
analyzed by the SEQUEST algorithm54 using a static Cys modification (+57 Da).  Data was 
searched against a human reverse-concatenated non-redundant FASTA database applying Uniprot 
identifiers.  MS2 spectra was assembled using DTASelect 2.055, with trypstat option applied.  
 
Pulldown experiments using biotin azide.  HEK293T cells stably expressing human PAD2 
(HEK293T PAD2) were cultured as previously described.41  Cells were grown to ~80% confluence 
(8 x 106 cells), trypsinized, and trypsin activity quenched with complete media.  The cells were 
harvested by centrifugation at 1000 x g for 2 min and washed 4x with 1x PBS.  Cells were 
resuspended in PBS at 8 x 106 cells/mL and 4 x 105 cells (0.6 mL) were added to 1.5 mL tubes and 
were treated with BB-F-Yne (25 µM) or BB-Cl-Yne (2.5 µM and 10 µM) in the presence of CaCl2 
(2 mM) at 37 ºC.  After 30 min, ionomycin (5 µM) was added and the cells incubated for 1 h 
followed by sonication at 4 ºC for 1 h.  Lysates were cleared by centrifugation at 21,000 x g for 15 
min.  The soluble protein fraction was isolated and quantified by the Detergent Compatible assay 
(DC assay, Biorad). Probe labeled proteins present in lysates (2 mg per tube) were then coupled to 
biotin azide using the click chemistry protocol described below.  HEK cell lysates (2 mg lysate per 
tube) were separately labeled with BB-F-yne (25 µM) and BB-Cl-yne (2.5 µM) for 1 h at 37 °C.  
Click chemistry was performed on all samples using biotin azide (100 µM), 1X TBTA (0.3 mM) 
and CuSO4 (1 mM) and incubating at room temperature for 2 h.  Samples were mixed well by 
vortexing them every 15 min.  The reaction mixture was then centrifuged and the pellet was 
washed with methanol and re-suspended in 1.2% SDS in PBS (w/v) sonication and heating (5 min, 
80 °C).  The SDS-solubilized samples were diluted with PBS (5 mL) for a final SDS concentration 
of 0.2%.  The solutions were incubated with 100 μL of streptavidin agarose beads (Thermo Fisher 
Scientific) at 4 °C for 16 h.  The solutions were then incubated at room temperature for 3 h. The 
beads were washed with PBS (2 × 5 mL), and water (5 mL).  The beads were pelleted by 
centrifugation (1,400 x g, 3 min) between washes. The washed beads were suspended in 8 M urea 
in PBS with 1.2% SDS (with 1X loading dye) and heated at 95 °C for 30 min and centrifuged.  The 
supernatant was separated by SDS-PAGE (4 – 20 % gel) and transferred to PVDF membranes 
(Biorad) at 150 V for 60 min.  The membranes were analyzed for the presence of PAD2 and other 
proteins of interest using the following antibodies:  anti-clathrin heavy chain antibody (Abcam, 
ab21679), anti-beta Tubulin antibody (Abcam, ab604), anti-beta actin antibody (Abcam, ab8227), 
anti-GAPDH antibody (Abcam ab9484), anti-RPL3 antibody (Abcam, ab154882), anti-Hsp90 
antibody (Abcam, ab13495), anti-glutamyl prolyl tRNA synthetase antibody (Abcam, ab85447), 
PADI2 antibody (Protein Tech, Cat No: 12110-1-AP).   
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Table 1. Inhibition of PAD isozymes by second generation inhibitors. 
Compound 
      PAD1 kinact/KI  









































   
BB-Cl-Yne (5) 6400 3600 10800 4900   
BB-F-Yne (6) 2050 1700 1100 3100   
a
kinact/KI was determined from a linear fit. 
b






Scheme 1. Synthesis of BB-F-Yne and BB-Cl-Yne 
  
Figure Legends 
Figure 1. (A and B) Development of Benzimidazole-Based ABPPs. (A) Progression of inhibitor 
design to current probe design. (B) Co-crystal structure of BB-F-amidine (4) bound to PAD4.  
(C) PAD2 (PDB: 4N2C) overlay with PAD4/BB-F-amidine (4) co-crystal structure in PyMOL. 
(D and E) Concentration dependent labeling of recombinant PAD2 with (D) BB-F-Yne and (E) 
BB-Cl-Yne.  PAD2 was treated with increasing concentrations of BB-F-Yne and BB-Cl-Yne for 
1 h followed by click chemistry with TAMRA-N3.  (F and G) The limit of detection for PAD2.  
Decreasing concentrations of PAD2 were treated with (F) BB-F-Yne and (G) BB-Cl-Yne for 1 h 
followed by click chemistry with TAMRA-N3.   
 
Figure 2. (A) Workflow showing probe labeling of mammalian cells by BB-F-Yne or BB-Cl-Yne 
followed by TAMRA-N3 mediated click chemistry.  HEK293T/PAD2 cells were treated with 
increasing concentrations of BB-F-Yne (B) or BB-Cl-Yne (C), 5μM ionomycin and 1 mM CaCl2 
and incubated at 37 °C for 1 h.  The cells were sonicated, and the probe labeled proteins were 
tagged with TAMRA-N3 to facilitate visualization after SDS-PAGE.  The visualized gel was 
transferred to a PVDF membrane and anti-PAD2 antibody was used to visualize PAD2 by western 
blot (shown in the bottom).  (D) Workflow showing probe labeling of mammalian cells by BB-F-
Yne or BB-Cl-Yne followed by biotin-N3 coupling. Labeled proteins were selectively separated 
using streptavidin beads.  (E) HEK293T/PAD2 cells were treated with increasing concentrations 
of BB-F-Yne or (F) BB-Cl-Yne, 5 μM ionomycin and 1 mM CaCl2 and incubated at 37 °C for 1 
h.  The cells were sonicated and the probe labeled proteins were tagged with Biotin-N3.  Biotin 
tagged proteins were then isolated on streptavidin agarose and the eluted proteins were probed for 
PAD2 by western blot.  The full gel is shown in supporting information (Figure S9). 
 Figure 3. (A) Workflow showing probe labeling of cell lysates by BB-F-Yne (25 μM) or BB-Cl-
Yne (2.5 μM) followed by coupling with biotin-N3. Labeled proteins were selectively separated 
using streptavidin agarose beads.  (B and C) Plot showing the difference in spectral counts between 
the sample and the control (Δ SC) for the experimental replicates. (D and E) A plot of average 
enrichment versus average spectral counts for BB-F-Yne and BB-Cl-Yne labeled cell lysates from 
proteomics analysis. 
 
Figure 4. (A) Workflow showing probe labeling of mammalian cells by BB-F-Yne or BB-Cl-Yne 
followed coupling to biotin-N3. Labeled proteins were selectively separated using streptavidin 
beads.  (B) HEK293T/PAD2 cells were treated with BB-Cl-Yne (2.5 μM), BB-F-Yne (25 μM), or 
DMSO. (C) HEK293T/PAD2 cells were treated with BB-Cl-Yne (10 μM), BB-F-Yne (25 μM) or 
DMSO, along with 5 μM ionomycin and 1 mM CaCl2 and incubated at 37 °C for 1h.  Cells were 
sonicated and the probe labeled proteins were tagged with Biotin-N3.  Biotin tagged proteins were 
then isolated on streptavidin agarose and the eluted proteins were probed for specific antibodies. 
Full image of the western blot along with more experimental details are given in the supporting 
information. See Figure S10 and S11.   
